

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ALLGEIER ET AL.

APPLICATION NO: HERewith

FILED: HERewith

FOR: MGLUR5 ANTAGONISTS FOR THE TREATMENT  
OF PAIN AND ANXIETY

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to calculation of the filing fees, please amend the application as follows:

IN THE SPECIFICATION

Page 1, directly beneath the title; please insert the following paragraph - - This is a continuation of International Application No. PCT/EP 99/07239, filed September 30, 1999, the contents of which are incorporated herein by reference. - -

IN THE CLAIMS

Please amend Claims 13-18 as follows:

13. (amended) A use according to claim 9, whereby the mGluR antagonist is a specific mGluR5 antagonist.
14. (amended) A use according to claim 9, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantially penetrate the CNS.
15. (amended) A use according to claim 9, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist which does not substantially cross the blood-brain barrier.

16. (amended) A use according to claim 9, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS.

17. (amended) A use according to claim 9, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally.

18. (amended) A use according to claim 9, whereby the condition to be treated is inflammatory or neuropathic pain.

Please add the following new claims:

- - 19. A composition according to claim 11, whereby the mGluR antagonist is a specific mGluR5 antagonist. - -

- - 20. A method according to claim 12, whereby the mGluR antagonist is a specific mGluR5 antagonist. - -

- - 21. A composition according to claim 11, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantially penetrate the CNS. - -

- - 22. A method according to claim 12, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantially penetrate the CNS. - -

- - 23. A composition according to claim 11, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist which does not substantially cross the blood-brain barrier. - -

- - 24. A method according to claim 12, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist which does not substantially cross the blood-brain barrier. - -

- - 25. A composition according to claim 11, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS. - -

- - 26. A method according to claim 12, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS. - -

- - 27. A composition according to claim 11, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally. - -

- - 28. A method according to claim 12, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally. - -

- - 29. A composition according to claim 11, whereby the condition to be treated is inflammatory or neuropathic pain. - -

- - 30. A method according to claim 12, whereby the condition to be treated is inflammatory or neuropathic pain. - -

#### REMARKS

By the foregoing amendment to the specification, a cross-reference has been inserted beneath the title on page 1.


Claims 13-18 have been amended to eliminate their multiple dependencies. In this connection, attached hereto is an Appendix which represents a marked-up version of the changes made to Claims 13-18 by the foregoing amendments.

New Claims 19-30 are directed to certain of the subject matter excised from Claims 13-18.

Early and favorable consideration of the claims is respectfully awaited.

Respectfully submitted,

Novartis Pharmaceuticals Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027

  
\_\_\_\_\_  
Joseph J. Ebrovian  
Agent for Applicants  
Reg. No. 28,631  
(908) 522-6921

Date: March 29, 2001

Encl.: Appendix (marked-up version of the changes made)

## APPENDIX

### VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 13-18 have been amended as follows:

13. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 to 12, whereby the mGluR antagonist is a specific mGluR5 antagonist.

14. (amended). A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 to 12, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantially penetrate the CNS.

15. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 to 12, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist which does not substantially cross the blood-brain barrier.

16. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 to 12, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS.

17. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 to 12, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally.

18. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 to 17, whereby the condition to be treated is inflammatory or neuropathic pain.